Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00235300
First received: October 6, 2005
Last updated: March 17, 2015
Last verified: March 2015